Joshua D Wallach
Biographic Data
| ID | 8450453 |
|---|---|
| NAME | Joshua D Wallach |
| GIVEN NAMES | Joshua D |
| FAMILY NAME | Wallach |
| SIGNATURE | WALLACH J D |
| AFFILIATIONS | Department of Environmental Health Sciences, Yale School of Public Health |
| ORCID | 0000-0002-2816-6905 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
Estimating the Prevalence of Transparency and Reproducibility-Related Research Practices in Psychology (2014–2017)
Psychologists are navigating an unprecedented period of introspection about the credibility and utility of their discipline. Reform initiatives emphasize the benefits of transparency and reproducibility-related research practices; however, adoption across the psychology literature is unknown. Estimating the prevalence of such practices will help to gauge the collective impact of reform initiatives, track progress over time, and calibrate future e…
Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017
The findings of this cross-sectional study indicate that most of the drugs granted FDA accelerated approval for original indications from 2012 to 2017 lacked confirmatory trials evaluating clinical outcomes to support conversion to standard approval. Automatic coverage mandates produced substantial CMS spending for drugs with unproven clinical benefits
No prominent works on this page.
Estimating the Prevalence of Transparency and Reproducibility-Related Research Practices in Psychology (2014–2017)
Psychologists are navigating an unprecedented period of introspection about the credibility and utility of their discipline. Reform initiatives emphasize the benefits of transparency and reproducibility-related research practices; however, adoption across the psychology literature is unknown. Estimating the prevalence of such practices will help to gauge the collective impact of reform initiatives, track progress over time, and calibrate future e…
Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017
The findings of this cross-sectional study indicate that most of the drugs granted FDA accelerated approval for original indications from 2012 to 2017 lacked confirmatory trials evaluating clinical outcomes to support conversion to standard approval. Automatic coverage mandates produced substantial CMS spending for drugs with unproven clinical benefits
Medicine (2 works) · Academic Writing and Publishing (1 work) · Authorization (1 work) · Clinical Psychology (1 work) · Clinical trial (1 work) · Confidence interval (1 work) · Credibility (1 work) · Drug (1 work) · Drug approval (1 work) · Environmental health (1 work)